Lantern Pharma shares surge 10.23% intraday after FDA approves STAR-001 IND application for pediatric CNS cancer trials.

Lantern Pharma surged 10.23% intraday, as it announced with Starlight Therapeutics that the FDA has approved the IND application for STAR-001 to begin a Phase I clinical trial in pediatric central nervous system cancers. The trial will be conducted at 14 cancer centers across the U.S., Canada, and Israel, evaluating STAR-001 as a monotherapy and in combination with spironolactone for relapsed/refractory pediatric CNS malignancies.